Feb 16, 2016, 08:00 ET Trulicity pen design based on needs of patients TORONTO, Feb
States worry about being too stringent for fear of taking away jobs, but the FDA cant possibly oversee thousands of compounding pharmacies alone, she said
Patients considering medically supervised weight loss should be aware of these restrictions: Section 503A pharmacies: Enforcement began April 22, 2025 Section 503B facilities: Must cease by May 22, 2025 Continued compounding may result in FDA enforcement actions Limited exceptions exist for documented allergies or specific medical needs Important Safety Note: The FDA strongly advises against using compounded semaglutide when FDA-approved alternatives are available
The starting point is always a proper consultation
Further studies are urgently needed to identify gender-related differences in efficacy and toxicity of GLP-1 RA in the pre- and post-bariatric population for a tailored approach to obesity management
10.1016/j.freeradbiomed.2016.03.009 Free Radic Biol Med
